217 related articles for article (PubMed ID: 32953889)
1. Differential Immunogenicity and Protective Efficacy Elicited by MTO- and DMT-Adjuvanted CMFO Subunit Vaccines against
Ullah N; Hao L; Wu Y; Zhang Y; Lei Q; Banga Ndzouboukou JL; Lin X; Fan X
J Immunol Res; 2020; 2020():2083793. PubMed ID: 32953889
[TBL] [Abstract][Full Text] [Related]
2. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
4. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
5. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against
Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N
Front Immunol; 2018; 9():310. PubMed ID: 29535714
[TBL] [Abstract][Full Text] [Related]
6. PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.
Ashhurst AS; Parumasivam T; Chan JGY; Lin LCW; Flórido M; West NP; Chan HK; Britton WJ
PLoS One; 2018; 13(3):e0194620. PubMed ID: 29554138
[TBL] [Abstract][Full Text] [Related]
7. A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation.
Ma J; Teng X; Wang X; Fan X; Wu Y; Tian M; Zhou Z; Li L
EBioMedicine; 2017 Aug; 22():143-154. PubMed ID: 28711483
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
9. Immunological characterization of chimeras of high specificity antigens from Mycobacterium tuberculosis H37Rv.
Fatma F; Tripathi DK; Srivastava M; Srivastava KK; Arora A
Tuberculosis (Edinb); 2021 Mar; 127():102054. PubMed ID: 33550109
[TBL] [Abstract][Full Text] [Related]
10. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.
Derrick SC; Yabe IM; Yang A; Kolibab K; Hollingsworth B; Kurtz SL; Morris S
Vaccine; 2013 Sep; 31(41):4641-6. PubMed ID: 23906890
[TBL] [Abstract][Full Text] [Related]
12. Oxidized Carbon Nanosphere-Based Subunit Vaccine Delivery System Elicited Robust Th1 and Cytotoxic T Cell Responses.
Sawutdeechaikul P; Cia F; Bancroft G; Wanichwecharungruang S; Sittplangkoon C; Palaga T
J Microbiol Biotechnol; 2019 Mar; 29(3):489-499. PubMed ID: 30691253
[TBL] [Abstract][Full Text] [Related]
13. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.
Ma J; Tian M; Fan X; Yu Q; Jing Y; Wang W; Li L; Zhou Z
Oncotarget; 2016 Sep; 7(39):63804-63815. PubMed ID: 27566581
[TBL] [Abstract][Full Text] [Related]
15. Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster.
Mao L; Xu L; Wang X; Xing Y; Wang J; Zhang Y; Yuan W; Du J; Shi Z; Ma J; Zhang J; Zhang X; Wang X
Tuberculosis (Edinb); 2022 May; 134():102186. PubMed ID: 35245739
[TBL] [Abstract][Full Text] [Related]
16. CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.
Hu S; Chen H; Ma J; Chen Q; Deng H; Gong F; Huang H; Shi C
J Appl Microbiol; 2013 Nov; 115(5):1203-11. PubMed ID: 23902541
[TBL] [Abstract][Full Text] [Related]
17. The importance of adjuvant formulation in the development of a tuberculosis vaccine.
Baldwin SL; Bertholet S; Reese VA; Ching LK; Reed SG; Coler RN
J Immunol; 2012 Mar; 188(5):2189-97. PubMed ID: 22291184
[TBL] [Abstract][Full Text] [Related]
18. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
Chaitra MG; Nayak R; Shaila MS
Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of Bacillus subtilis spores and monophosphoryl lipid A as adjuvants of protein-based mycobacterium tuberculosis-based vaccines: partial requirement for interleukin-17a for induction of protective immunity.
Esparza-Gonzalez SC; Troy AR; Izzo AA
Clin Vaccine Immunol; 2014 Apr; 21(4):501-8. PubMed ID: 24477855
[TBL] [Abstract][Full Text] [Related]
20. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
